Introduction
============

In an aging European population, osteoporosis has become a major public health problem. It increases morbidity and mortality ([@b1-etm-0-0-7746]--[@b3-etm-0-0-7746]) and it leads to high direct and indirect medical costs ([@b4-etm-0-0-7746],[@b5-etm-0-0-7746]) for society due to its hallmark clinical manifestation: Fragility fractures, particularly vertebral and hip fractures. The population at risk includes post-menopausal females, the elderly, patients with long-term glucocorticoid treatment and patients with chronic inflammatory diseases, e.g. rheumatoid arthritis (RA). Patients with this auto-immune inflammatory disease constitute a special subpopulation of patients prone to osteoporosis, since they possess multiple risk factors for systemic bone loss: Chronic inflammation of uncontrolled disease activity ([@b6-etm-0-0-7746]), higher prevalence of early menopause ([@b7-etm-0-0-7746]), increased smoking and alcohol consumption due to RA-associated stress and depression ([@b8-etm-0-0-7746]--[@b10-etm-0-0-7746]), physical disability and sedentary behavior caused by RA radiographic progression ([@b11-etm-0-0-7746],[@b12-etm-0-0-7746]) and treatment with glucocorticoids ([@b13-etm-0-0-7746]), which are independently involved in lowering bone mineral density (BMD). Complex management principles of RA should include strategies to reduce these risk factors and should promote osteoporosis screening among RA patients. Unfortunately, a large fraction of patients is still being diagnosed with osteoporosis at the late stage, after a fragility fracture. Thus, early detection of osteoporosis and prevention of its complications are important and require a reliable and reproducible method, accessible to rheumatologists in all clinical settings. Dual-energy X-ray absorptiometry (DXA) is the current validated 'gold standard' for the diagnosis of osteoporosis, fracture risk estimation and follow-up of anti-osteoporotic treatment ([@b14-etm-0-0-7746]--[@b16-etm-0-0-7746]), since it is non-invasive, simple, precise, fast, less expensive than other imaging techniques, including computed tomography and magnetic resonance imaging, and more sensitive than quantitative ultrasound (QUS) ([@b17-etm-0-0-7746]). DXA and QUS offer the advantage of body composition estimation. However, QUS may have particular advantages over DXA, which make it suitable for a potentially wider use in the primary screening or pre-screening of osteoporosis and the identification of cases requiring DXA scanning ([@b18-etm-0-0-7746],[@b19-etm-0-0-7746]): It is less expensive, does not use ionising radiation, uses smaller hardware and is portable. A recently introduced QUS method that integrates ultrasound imaging and radiofrequency signals is being used for the diagnosis of osteoporosis and it produced results comparable to those obtained with the DXA method ([@b20-etm-0-0-7746],[@b21-etm-0-0-7746]). To the best of our knowledge, this technique has never been used in a controlled study environment to assess BMD in Romanian RA patients and healthy controls. Therefore, the objective of the present study was to observe whether this innovative QUS technique is reliable compared to DXA in a typical sample of Romanian patients. In the first stage of the present study, Romanian RA patients and healthy controls were pre-screened for osteoporosis using a novel QUS machine, in order to compare the two groups in terms of bone parameters and to observe the influence of body composition on BMD and osteoporosis outcomes.

Patients and methods
====================

### Patients and variables

The present study prospectively included post-menopausal females diagnosed with RA, who also fulfilled the latest classification criteria ([@b22-etm-0-0-7746]). Age-matched controls were recruited from healthy post-menopausal females presenting at the rheumatology department in the same time period due to osteoarthritis or occupational musculoskeletal complaints. All of the subjects were examined between January and June 2018 in a random order of arrival at two rheumatology clinics of university hospitals with national addressability (Rheumatology Department of Sfânta Maria Clinical Hospital and 'Dr I. Cantacuzino' Clinical Hospital). Neither the RA patients nor the controls had been subjected to a DXA scan or had a known diagnosis of osteoporosis prior to inclusion in the study; therefore, none of them were receiving any active pharmacologic treatment (bisphosphonates, hormone replacement therapy, teriparatide, denosumab, strontium ranelate or vitamin D supplements). Prior to any study procedure, each patient provided written informed consent and the study was approved by the Ethics Committee of Sfanta Maria Clinical Hospital (no. 21440; 22.12.2017). The patients were evaluated for the following exclusion criteria that were applied: Age \<18 years; overlap syndromes of RA with other chronic auto-immune inflammatory rheumatologic disorders or their presence in the control group; causes of secondary osteoporosis, either in the patient\'s history or diagnosed during the study by each attending physician (cancer, celiac disease, chronic liver disease, chronic pancreatitis, chronic renal disease, chronic obstructive pulmonary disease, Cushing\'s disease, cystic fibrosis, diabetes mellitus, hemoglobinopathies, heparin treatment, hypogonadism, hyperthyroidism, inflammatory bowel disease, immobility, malabsorption). Body height and weight were measured in an upright anatomical position, with light clothing and no shoes, using a mechanical scale (0.1 kg maximal error) and a stadiometer (0.3 cm maximal error). The body mass index (BMI) was calculated by dividing the body weight by the square of the height and the following weight categories were defined ([@b23-etm-0-0-7746]): Underweight (BMI\<18.5 kg/m^2^), normal weight (18.5≤BMI\<25 kg/m^2^), overweight (25≤BMI\<30 kg/m^2^) and obese (BMI≥30 kg/m^2^).

### BMD measurement

All of the measurements were performed by a single trained technologist using an EchoS machine (Echolight^®^; Echolight SRL), which uses quantitative ultrasonometry to estimate bone density and structure. The system is equipped with a convex 3.5 MHz transducer, which simultaneously detects B-mode ultrasound signals and unprocessed radiofrequency signals. Those which are analyzed by the machine\'s statistical algorithm (EchoStudio^®^; Echolight SRL) for each region of interest (ROI), taking into account the patient\'s ethnicity, age, sex and BMI and comparing them to a database of \~10,000 subjects ([@b18-etm-0-0-7746],[@b20-etm-0-0-7746],[@b24-etm-0-0-7746]--[@b26-etm-0-0-7746]). The ROI for each patient included the usual sites for the diagnosis of osteoporosis: The lumbar spine (L1-L4 vertebrae approached from the abdomen) and the femoral necks. The machine\'s software outputs the following measurements: 10-year risk of major osteoporotic and hip fractures (Fracture Risk Assessment Tool; FRAX^®^), calculated according to the established algorithm ([@b27-etm-0-0-7746]), BMD (g/cm^2^) with T and Z scores \[standard deviations (SD)\], body fat percentage and basal metabolic rate \[BMR (kcal/day)\]. The producer reported the following quality and precision ([@b15-etm-0-0-7746],[@b28-etm-0-0-7746]) parameters for the machine: Minimal detectable change of 0.013 g/cm^2^ for the spine and 0.008 g/cm^2^ for the hip; intra-operator reproducibility of 0.4% for the spine and 0.3% for the hip; inter-operator reproducibility of 0.54% for the spine and 0.41% for the hip; diagnostic correlation with DXA of 93.1% for the spine and 94.2% for the hip. In the present study, osteoporosis was defined by a T score for the spine or either hip of ≤-2.5 SD.

### Statistics

Normality of distribution of data was assessed using descriptive statistics, normality plots and Lillefors corrected Kolmogorov-Smirnov tests. Normally distributed continuous variables are expressed as the mean ± standard deviation, while non-normally distributed variables are expressed as the median (minimum-maximum). Qualitative variables are expressed as absolute frequency (fraction of subgroup). The correlations of normally distributed continuous variables were assessed using 2-tailed partial correlations controlling for recorded confounders. The difference of continuous variables between subgroups (RA and controls or RA patients with or without osteoporosis) was assessed by independent-samples t-tests or Mann-Whitney U-tests, depending on their normality of distribution, while differences of nominal variables were assessed with χ^2^ tests. The distribution of BMD measurements among RA patients according to weight category was assessed using independent-samples Kruskal-Wallis tests. P\<0.05 was considered to indicate statistical significance. Statistical analysis was performed using SPSS v.20 for Windows (IBM Corp.).

Results
=======

### General characteristics

The study included 225 subjects: 106 RA patients (47.1%), with an average age of 65±8 years and 119 controls (52.9%) with an average age of 64±13 years ([Table I](#tI-etm-0-0-7746){ref-type="table"}). The median disease duration of RA was 3.2 (1.5--42.0) years and all RA patients were receiving at least one conventional synthetic disease-modifying anti-rheumatic drug: Methotrexate (77.4%), leflunomide (18.9%), sulfasalazine (12.3%) and/or hydroxychloroquine (8.5%). All of the RA patients had received glucocorticoids for different periods of time during the disease course, but 14 patients (13.2%) were still taking glucocorticoids at the time of study inclusion. The mean dose of glucocorticoids in the 3 months prior to study inclusion was 8.9 (4.0--15.0) mg of prednisone/day or equivalent.

### Inter-group comparison

Comparing the two groups, significant differences became apparent: The RA patients had a significantly lower body weight and BMI and BMR than the controls, although the prevalence of obesity and body fat percentage differed insignificantly ([Table I](#tI-etm-0-0-7746){ref-type="table"}). Regarding bone measurements, RA patients had a significantly lower spine and hip BMD ([Fig. 1](#f1-etm-0-0-7746){ref-type="fig"}), higher fracture risks according to FRAX scores and higher prevalence of T score-defined osteoporosis ([Table I](#tI-etm-0-0-7746){ref-type="table"}).

### RA subgroup analysis

RA patients were also studied independently regarding their osteoporosis status: Patients with or without osteoporosis were compared ([Table II](#tII-etm-0-0-7746){ref-type="table"}). Compared to non-osteoporotic RA patients, RA patients with osteoporosis were significantly older and had a longer menopause duration, but they had a significantly lower percentage of body fat (28% compared to 37% respectively; P\<0.001; [Fig. 2](#f2-etm-0-0-7746){ref-type="fig"}), BMI, prevalence of obesity and BMR ([Table II](#tII-etm-0-0-7746){ref-type="table"}). Median BMD values increased proportionally and significantly with weight category ([Fig. 3](#f3-etm-0-0-7746){ref-type="fig"}). Body fat and BMD at all three scanning sites were significantly and positively correlated when controlling for age, menopause duration and BMI ([Table III](#tIII-etm-0-0-7746){ref-type="table"}).

Discussion
==========

Regarding the aims of the present study, implementation of the novel QUS technique revealed a higher prevalence of osteoporosis among RA patients compared to controls, which in turn caused higher fragility fracture risks according to FRAX, which is well documented in the literature in studies using DXA ([@b29-etm-0-0-7746]--[@b31-etm-0-0-7746]). The fraction of RA patients with osteoporosis was previously reported to be up to 50% ([@b30-etm-0-0-7746]), but the 28.3% prevalence of osteoporosis among the RA patients in the present study is similar to that determined by other European DXA-defined studies on the prevalence of osteoporosis: For instance, Hauser *et al* ([@b29-etm-0-0-7746]) reported that 29.9% of their RA patients had osteoporosis, while Mobini *et al* ([@b31-etm-0-0-7746]) reported a slightly higher prevalence of 32.3%. RA is highly associated with osteoporosis: The rate of BMD decline in females with RA is significantly higher than that of controls in all age groups ([@b29-etm-0-0-7746]) and 10% of females with RA with a normal initial BMD develop osteoporosis within a decade ([@b32-etm-0-0-7746]). Positive rheumatoid factor and anti-citrullinated protein antibodies ([@b31-etm-0-0-7746]), RA disease duration ([@b30-etm-0-0-7746]), quality of life ([@b30-etm-0-0-7746]) and glucocorticoids ([@b33-etm-0-0-7746]) are specific risk factors for osteoporosis in RA, proving that the association of the two diseases is causal. This assumption is further documented by genetic studies, which revealed \>30 genetic factors of the RA-osteoporosis association ([@b34-etm-0-0-7746]), including the 14-3-3ε protein ([@b35-etm-0-0-7746]) and polymorphisms of vitamin D receptors ([@b36-etm-0-0-7746],[@b37-etm-0-0-7746]) and of receptor activator of NF-κB ([@b38-etm-0-0-7746]). This strong link is the fundamental reason for the requirement of intensive and extensive osteoporosis screening and treatment of RA patients, a goal which may be achieved by exploiting the physical advantages of QUS methods.

In terms of body composition, an insignificant difference in body fat was observed among RA patients and controls, as estimated by the novel QUS method, a result which replicates a similar previous observation of our group using DXA ([@b39-etm-0-0-7746]). Considering the fact that the RA patients of the present study had a significantly lower median body weight and BMD in the selected ROI compared with those of the controls, it may be hypothesized that the RA patients had a lower muscle mass than the controls, which is in accordance with literature reports of higher prevalence of cachexia and sarcopenia among RA patients ([@b40-etm-0-0-7746]--[@b42-etm-0-0-7746]), and/or that there was a selection bias of controls (the fact that these subjects solicited medical attention may translate to a higher morbidity toll than the remainder of the healthy Romanian population, including obese individuals). Of note, in the present study, the RA patients with osteoporosis had a significantly lower median BMI and QUS-estimated body fat than the RA patients without osteoporosis. If this lower BMI is explained by a lower body fat mass, this observation is explainable by the trend reported in the general population of a low BMI being associated with an increased risk of osteoporosis ([@b43-etm-0-0-7746],[@b44-etm-0-0-7746]), which translates into the lack of the protective effect of adiposity against systemic bone loss. If the observed lower BMI of RA patients with osteoporosis was not due to their lower body fat mass, it must be assumed that these patients had a loss of therapeutic control of their disease activity which is expected to decrease BMI through cytokine production. In the association of BMI and BMD, the significant inflexion point of increasing BMD appears to be between BMI-defined overweight and obese RA patients and between BMI-defined normal-weight and overweight controls, which graphically demonstrates that overweight RA patients experience the same BMD effect as normal-weight controls, reaffirming the requirement to lower BMI cutoffs in RA patients, since there is DXA evidence that the traditional 30 kg/m^2^ cutoff for obesity is too high for RA patients ([@b45-etm-0-0-7746]). It may also suggest that there is a critical adipose tissue mass \[or its biochemical products, including estrogens, androgens and leptin ([@b46-etm-0-0-7746])\], which is required counteract systemic bone loss. Clinicians should be aware of body composition trends in their RA patients, as evidence suggests that patients with early RA tend to lose their lean body mass status and gain truncal fat distribution ([@b47-etm-0-0-7746]), and that these modifications in body composition may be significantly predicted by RA-specific variables, including disease duration, disease activity scores and radiographic progression ([@b48-etm-0-0-7746]). Complex management of RA (control of disease activity and cardiovascular risk factors) should aim to prevent or reverse these changes in body composition, with additional long-term effects or lowering of mortality by decreasing cardiovascular and fracture complications.

There are several limitations of the present study, which may influence the relevance of the results, including its cross-sectional design (which, at this time, did not allow for follow-up QUS scans in order to assess the evolution in time and the effect of therapeutic intervention), hospital-recruited study samples (which may have been biased regarding the presence of comorbidities) and the lack of data regarding disease activity (including composite disease activity scores, which would have allowed for evaluation of the association of QUS measurements and the inflammation burden). Future research efforts will aim to bring improvements to the design of the present preliminary study on the novel QUS technique in detecting osteoporosis in post-menopausal females with or without RA, including direct comparison with DXA results, inclusion of more study groups with other rheumatic diseases and, in a longer term, to evaluate the cost-effectiveness of this portable QUS method in a wider screening program.

This innovative, non-ionizing technique Radiofrequency Echographic Multi Spectrometry (REMS) used for diagnosing osteoporosis was recently evaluated through a multicenter study that involved 1914 women and the results obtained with this method were significantly in agreement with those obtained using the gold standard lumbar spine and femoral neck DXA evaluation. Regarding its diagnostic capability, REMS evaluation had a sensitivity and specificity of \>90% for the two anatomic sites that were measured ([@b48-etm-0-0-7746]). It should be mentioned that on 21 September 2018, at the meeting of the International Scientific Advisory Board of Echolight in Florence, Prof. Dr. Jean-Yves Reginster, president of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), signed a letter in the name of the organization, recommending the inclusion of REMS technology into clinical practice guidelines for the diagnosis and treatment of osteoporosis. The letter mentioned the fact that ESCEO is considering to publish a position paper discussing the potentialities of REMS technology for the early diagnosis of osteoporosis and for monitoring treatment effects. This method will be considered at the next revision of the ESCEO clinical practice guidelines.

In conclusion, osteoporosis is prevalent among RA patients, increasing their fragility fracture risk, and is part of a more complex pathological process of alteration of body mass composition, involving BMI and fat mass. The novel scanning technique, which combines B-mode ultrasound and radiofrequency signals, is able to replicate the results of the established DXA measurements of BMD and is potentially suitable for the screening of wide populations for osteoporosis.
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![Differences in BMD between RA patients and controls, measured at (A) the lumbar spine (median, 0.87 vs. 0.87 g/cm^2^; \*P=0.035, t-test) and (B) the left femoral neck (median, 0.67 vs. 0.71 g/cm^2^; ^\#^P=0.021, t-test). RA, rheumatoid arthritis; BMD, bone mineral density.](etm-18-03-1661-g00){#f1-etm-0-0-7746}

![Differences in body fat between rheumatoid arthritis patients with osteoporosis (median 28.1%) and without osteoporosis determined with QUS (median, 36.7%; P\<0.001; Mann-Whitney U-test). QUS, quantitative ultrasound.](etm-18-03-1661-g01){#f2-etm-0-0-7746}

![Distribution of median BMD among RA patients and controls at the spine, left and right femoral neck according to weight category. (A) For RA patients: Underweight (n=5; sBMD=0.69 g/cm^2^; lfnBMD=0.45 g/cm^2^; rfnBMD=0.47 g/cm^2^), normal weight (n=43; sBMD=0.83 g/cm^2^; lfnBMD=0.58 g/cm^2^; rfnBMD=0.62 g/cm^2^), overweight (n=33; sBMD =0.87 g/cm^2^; lfnBMD=0.69 g/cm^2^; rfnBMD=0.64 g/cm^2^) and obese (n=25; sBMD=0.98 g/cm^2^; lfnBMD=0.85 g/cm^2^; rfnBMD=0.78 g/cm^2^). (B) For controls: Underweight (n=2), normal weight (n=34; sBMD=0.84 g/cm^2^; lfnBMD=0.61 g/cm^2^; rfnBMD=0.61 g/cm^2^), overweight (n=49; sBMD=0.91 g/cm^2^; lfnBMD=0.72 g/cm^2^; rfnBMD=0.72 g/cm^2^) and obese (n=34; sBMD=0.99 g/cm^2^; lfnBMD=0.82 g/cm^2^; rfnBMD=0.85 g/cm^2^). All comparisons were tested with Kruskal-Wallis tests (P\<0.001 for all). RA, rheumatoid arthritis; sBMD, spine bone mineral density; l/rfn, left/right femoral neck.](etm-18-03-1661-g02){#f3-etm-0-0-7746}

###### 

Comparison of clinicopathological characteristics between subjects with RA and controls.

  Parameter                          Controls (n=119)      RA (n=106)            P-value
  ---------------------------------- --------------------- --------------------- -------------------------------------------------------
  Age (years)                        64±13                 65±8                  0.448^[a](#tfn2-etm-0-0-7746){ref-type="table-fn"}^
  Menopause (years)                  10 (1--42)            17 (1--45)            0.223^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Height (m)                         1.6±0.1               1.6±0.1               0.166^[a](#tfn2-etm-0-0-7746){ref-type="table-fn"}^
  Weight (kg)                          68 (42--109)        65 (45--95)           0.011^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  BMI (kg/m^2^)                        27 (18--41)         26 (18--38)           0.039^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Obesity (%)                          34 (28.6%)            25 (23.6%)          0.396^[c](#tfn4-etm-0-0-7746){ref-type="table-fn"}^
  Body fat (%)                       35.4±5.5              35.5±6.6              0.257^[a](#tfn2-etm-0-0-7746){ref-type="table-fn"}^
  BMR (1,000 kcal/day)                 1.3 (0.9--2.8)        1.2 (0.8--2.6)      0.038^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Spine T-score (SD)                   --1.8 (−3.2--1.5)     --1.9 (−4.2--1.2)   0.110^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Spine BMD (g/cm^2^)                0.89±0.13             0.87±0.09             0.035^[a](#tfn2-etm-0-0-7746){ref-type="table-fn"}^
  Spine FRAX-mof (%)                   4.1 (1.2--6.2)        6.3 (1.9--15.2)     \<0.001^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Spine FRAX-hf (%)                  0.8 (0--8.2)            2.1 (0.8--12.5)     \<0.001^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Left femoral neck T-score (SD)       --1.7 (−2.8--1.2)     --2.0 (−3.9--0.8)   0.039^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Left femoral neck BMD (g/cm^2^)    0.71±0.13             0.67±0.12             0.021^[a](#tfn2-etm-0-0-7746){ref-type="table-fn"}^
  Left hip FRAX-mof (%)              4.9 (0--8.1)          6.6 (1--13.2)         \<0.001^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Left hip FRAX-hf (%)               1.2 (0--5.2)            1.8 (0.9--11.6)     \<0.001^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Right femoral neck T-score (SD)      --1.7 (−2.7--1.5)     --2.0 (−3.7--1.2)   0.030^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Right femoral neck BMD (g/cm^2^)   0.71±0.12             0.67±0.12             0.041^[a](#tfn2-etm-0-0-7746){ref-type="table-fn"}^
  Right hip FRAX-mof (%)             4.6 (0--5.1)          6.4 (1--12.8)         \<0.001^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Right hip FRAX-hf (%)              1.0 (0--4.8)            1.7 (1.1--10.2)     \<0.001^[b](#tfn3-etm-0-0-7746){ref-type="table-fn"}^
  Osteoporosis (%)                     16 (13.4%)            30 (28.3%)          0.006^[c](#tfn4-etm-0-0-7746){ref-type="table-fn"}^

Values expressed as

the mean (standard deviation) if normally distributed with significant differences between groups assessed with independent-samples t-tests

the median (minimum-maximum) if non-normally distributed and statistical significance was assessed with Mann-Whitney U-tests or

absolute frequency (percent proportion from subgroup) if nominal and χ^2^ tests were used to assess significant differences between groups. BMD, bone mineral density; BMI, body mass index; BMR, basal metabolic rate; FRAX, Fracture Risk Assessment Tool; hf, hip fracture; mof, major osteoporotic fracture; RA, rheumatoid arthritis; SD, standard deviation.

###### 

Comparison of clinicopathological parameters between RA patients with and without osteoporosis.

                         Osteoporosis                      
  ---------------------- ---------------- ---------------- -------------------------------------------------------
  Age (years)            60 (42--82)      69 (36--84)      \<0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^
  Menopause (years)      13 (1--38)       26 (1--42)       \<0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^
  Height (cm)            161 (151--185)   160 (152--182)   \<0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^
  Weight (kg)            70 (46--95)      55 (42--82)      \<0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^
  BMI (kg/m^2^)          27 (18--36)      22 (18--31)      \<0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^
  Obesity (%)            23 (21.7%)       2 (1.9%)         0.010^[b](#tfn7-etm-0-0-7746){ref-type="table-fn"}^
  Body fat (%)           37 (30--61)      28 (28--52)      0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^
  BMR (1,000 kcal/day)   1.3 (0.8--2.8)   1.1 (0.8--2.5)   \<0.001^[a](#tfn6-etm-0-0-7746){ref-type="table-fn"}^

Osteoporosis was defined by a spine or either hip T score of ≤-2.5 SD. Values expressed as

the median (minimum-maximum) if non-normally distributed and statistical significance was assessed with Mann-Whitney U-tests or

absolute frequency (percent proportion from subgroup) if nominal and χ^2^ tests were used to assess significant differences between groups. BMI, body mass index; BMR, basal metabolic rate; RA, rheumatoid arthritis; SD, standard deviation.

###### 

Correlation of body fat with BMD controlling for age, menopause duration and body mass index.

                  All (n=225)   RA group (n=106)   Control group (n=119)                     
  --------------- ------------- ------------------ ----------------------- --------- ------- ---------
  Spine BMD       0.663         \<0.001            0.645                   \<0.001   0.674   \<0.001
  Left hip BMD    0.622         \<0.001            0.691                   \<0.001   0.572   \<0.001
  Right hip BMD   0.697         \<0.001            0.514                     0.003   0.777   \<0.001

BMD, bone mineral density; RA, rheumatoid arthritis.

[^1]: Contributed equally
